Bevyxxa (betrixaban) NEW PRODUCT SLIDESHOW
|
|
- Kerrie Nichols
- 6 years ago
- Views:
Transcription
1 Bevyxxa (betrixaban) NEW PRODUCT SLIDESHOW
2 Introduction Brand name: Bevyxxa Generic name: Betrixaban Pharmacological class: Factor Xa inhibitor Strength and Formulation: 40mg, 80mg; caps Manufacturer: Portola Pharmaceuticals How supplied: Caps 100 Legal Classification: Rx
3 Bevyxxa
4 Indications Prophylaxis of venous thromboembolism (VTE) in adults hospitalized for an acute medical illness who are at risk for thromboembolic complications Limitations of use: safety and efficacy not established in patients with prosthetic heart valves
5 Mechanism of Action Betrixaban selectively blocks the active site of FXa and does not require a cofactor (such as anti-thrombin III) for activity Betrixaban decreases thrombin generation It has no direct effect on platelet aggregation
6 Dosage & Administration Take with food Initially 160mg as a single dose, followed by 80mg once daily for days Severe renal impairment (CrCl 15 <30mL/min) or concomitant P-gp inhibitors: initially 80mg as a single dose, followed by 40mg once daily for days
7 Considerations for Special Populations Pediatric: Not established Pregnancy: Risk of pregnancy-related hemorrhage Nursing mothers: Consider clinical need and potential adverse effects Elderly: No clinically significant differences Renal impairment: See Dosage & Administration; monitor closely and evaluate any signs/symptoms of blood loss Hepatic impairment: Not recommended
8 Contraindications Active pathological bleeding
9 Warnings/Precautions Increased risk of spinal/epidural hematoma in anticoagulated patients receiving neuraxial anesthesia or undergoing spinal puncture (see full labeling); monitor for signs/symptoms of neurological impairment Increased risk of bleeding; monitor for signs/symptoms of blood loss; discontinue if active pathological hemorrhage occurs
10 Interactions Increased risk of bleeding with concomitant aspirin, antiplatelets, anticoagulants, heparin, thrombolytics, SSRIs, SNRIs, and NSAIDs Potentiated by P-gp inhibitors (eg, amiodarone, azithromycin, verapamil, ketoconazole, clarithromycin): reduce Bevyxxa dose (see Adult); monitor closely and evaluate any signs/symptoms of blood loss
11 Adverse Reactions Bleeding events (may be serious or fatal) Urinary tract infection Constipation Hypokalemia Hypertension Headache Nausea Diarrhea Hypersensitivity reactions
12 Clinical Studies APEX was a randomized, double-blind, multinational study comparing extended duration Bevyxxa (35 42 days) vs short duration enoxaparin (6 14 days) for VTE prevention in acutely medically ill hospitalized patients with risk factors for VTE (N=7,513)
13 Clinical Studies At study initiation, eligible patients were required to have 1 of the following additional VTE risk factors: 75 years old years old with D-dimer 2 ULN years old with D-dimer 2 ULN and history of VTE or cancer
14 Clinical Studies Study patients were randomized to either: Bevyxxa 160mg on Day 1 then 80mg once daily for 35 to 42 days with enoxaparin subcutaneous placebo once daily for 6 to 14 days Enoxaparin 40mg subcutaneously once daily for 6 to 14 days and Bevyxxa placebo orally once daily for 35 to 42 days
15 Clinical Studies The efficacy of Bevyxxa was based on the composite outcome of the occurrence of any of the following events up to Day 35 visit: Asymptomatic proximal DVT Symptomatic proximal or distal DVT Non-fatal pulmonary embolism (PE) VTE-related death
16 Clinical Studies The composite outcome was observed in 4.4% of Bevyxxa-treated patients vs 6.0% of enoxaparin-treated patients (relative risk [RR] 0.75, 95% CI: 0.61, 0.91) Symptomatic events were seen in 0.9% of Bevyxxa-treated patients vs 1.5% of enoxaparin-treated patients (RR 0.64, 95% CI: 0.42, 0.98)
17 Clinical Studies Patients with severe renal impairment who received Bevyxxa 40mg showed similar VTE rates to the enoxaparin arm Composite outcome (6.9% vs 6.7%, RR 1.0, 95% CI: 0.45, 2.23) Symptomatic events (2.3% vs 2.0%)
18 Clinical Studies Patients who received Bevyxxa 40mg because of concomitant P-gp inhibitors showed similar VTE rates to enoxaparin Composite outcome (4.9% vs 5.1%, RR 1.0, 95% CI: 0.63, 1.60) Symptomatic events (1.3% vs 1.6%) For more clinical trial data, see full labeling
19 New Product Monograph For more information view the product monograph available at:
New Drug Evaluation: Betrixaban Capsules
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
Tuesday, March 20, Oppenheimer & Co. Annual Healthcare Conference
ca Tuesday, March 20, 2018 Oppenheimer & Co. Annual Healthcare Conference Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
Betrixaban (Bevyxxa) A Direct-Acting Oral Anticoagulant Factor Xa Inhibitor
Betrixaban (Bevyxxa) A Direct-Acting Oral Anticoagulant Factor Xa Inhibitor Jessica W. Skelley, PharmD, BCACP; Angela R. Thomason, PharmD, BCPS; and Jeffery C. Nolen, PharmD Candidate INTRODUCTION Venous
Scottish Medicines Consortium
Scottish Medicines Consortium fondaparinux, 2.5mg/0.5ml, solution for injection (Arixtra ) No. (287/06) GlaxoSmithKline 7 July 2006 The Scottish Medicines Consortium has completed its assessment of the
The Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2
News Release Bayer HealthCare AG Corporate Communications 51368 Leverkusen Germany Phone +49 214 30 1 www.news.bayer.com Venous Blood Clot Prevention after Hip Replacement Surgery: The Lancet Publishes
BETRIXABAN TO PREVENT PE, DVT, STROKE: MEDICALLY ILL PATIENTS Samuel Z. Goldhaber, MD Director, Thrombosis Research Group Section Head, Vascular
BETRIXABAN TO PREVENT PE, DVT, STROKE: MEDICALLY ILL PATIENTS Samuel Z. Goldhaber, MD Director, Thrombosis Research Group Section Head, Vascular Medicine Cardiovascular Division Brigham and Women s Hospital
Anti- THrombosis with Enoxaparin in intubated Adolescents
Anti- THrombosis with Enoxaparin in intubated Adolescents E. Vincent S. Faustino, MD, MHS October 2017 NHLBI submission S L I D E 0 Research question, central hypothesis and primary aim Research Question
DRUG NAME : Clexane (enoxaparin) Pre-Filled Syringes
NHS ONEL & Barking, Havering & Redbridge University Hospitals Trust Shared Care Guidelines DRUG NAME : Clexane (enoxaparin) Pre-Filled Syringes DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AS AND FILED
Enoxaparin sodium 150mg (equivalent to 15,000 IU anti-xa. activity) in 0.2ml water for injections. activity) in 0.4ml water for injections
1. NAME OF THE MEDICINAL PRODUCT Clexane (Lovenox) Syringes Clexane (Lovenox) Forte Syringes 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Clexane (Lovenox) Syringes (100mg/ml) 20mg Injection 40mg Injection
Clinical Policy Guidelines. Management of patients on antithrombotic agents undergoing colonoscopy procedure following positive FOB test.
NHS GREATER GLASGOW AND CLYDE BOWEL SCREENING PROGRAMME Clinical Policy Guidelines Management of patients on antithrombotic agents undergoing colonoscopy procedure following positive FOB test. Date to
Mark Crowther, MD, MSc, FRCPC. Co-authors. Professor of Medicine, McMaster University, Canada
Reversal of Enoxaparin-Induced Anticoagulation in Healthy Subjects by Andexanet Alfa (PRT064445), An Antidote for Direct and Indirect fxa Inhibitors A Phase 2 Randomized, Double-Blind, Placebo Controlled
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
Challenges of VTE Prophylaxis in. Orthopaedics. Prevalence of DVT in Orthopaedic Surgery Without Prophylaxis
Grand Rounds Scripps Green Hospital May 5, 2010 Challenges of VTE Prophylaxis in Orthopaedics C. W. Colwell, Jr., M.D. At Scripps Clinic Challenges of VTE Prophylaxis in Orthopaedics I have a potential
Coordinated Primary Options Service. DVT Management Plan. Management options using Dabigatran or Warfarin
Coordinated Primary Options Service DVT Management Plan Management options using Dabigatran or Warfarin Name NHI DOB Ethnicity Gender Address Contact Information Mobile Home Treatment commenced date *CPO
LVHN Scholarly Works. Lehigh Valley Health Network. Joseph G. Ottinger RPh, MS, MBA, BCPS Lehigh Valley Health Network,
Lehigh Valley Health Network LVHN Scholarly Works Department of Pharmacy Retrospective Evaluation of Delayed Administration of Fondaparinux in Providing Comparable Safety and Efficacy Outcomes in Patients
Perioperative management of patients on warfarin requiring elective surgery Dr K Boyd, Mrs S Doyle
CLINICAL GUIDELINES ID TAG Title: Author: Speciality / Division: Directorate: Perioperative management of patients on warfarin requiring elective surgery Dr K Boyd, Mrs S Doyle Haematology Acute Date Uploaded:
Physician Orders - Adult
Physician Orders - Adult attach patient label here Title: Direct Thrombin Inhibitor (DTI) Protocol Orders Height: cm Weight: kg Allergies: [ ] No known allergies [ ]Medication allergy(s): [ ] Latex allergy
NEW ORAL ANTICOAGULANTS FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS IN THE FOOT AND ANKLE
NEW ORAL ANTICOAGULANTS FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS IN THE FOOT AND ANKLE Matthew Q. McCammon, DPM INTRODUCTION Venous thromboembolism (VTE) is a common cause of morbidity and mortality. Each
Peer Review Report # 2. Low Molecular Weight Heparins
20 th Expert Committee on Selection and Use of Essential Medicines Peer Review Report # 2 Low Molecular Weight Heparins (1) Does the application adequately address the issue of the public health need for
ENOXAPARIN AHFS??? Class: Low molecular weight heparin (LMWH).
ENOXAPARIN AHFS??? Class: Low molecular weight heparin (LMWH). Indications: Prevention and treatment of deep vein thrombosis, pulmonary embolism, thrombophlebitis migrans, disseminated intravascular coagulation
Session 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 1 of 4 Session 1 Topics Review of coagulation and the vascular phase of hemostasis Unfractionated heparin Low molecular
ANTICOAGULANT THERAPY ANTICOAGULANT THERAPY REVISITED 2005
ANTICOAGULANT THERAPY REVISITED 2005 or, Which one(s) of these (#$%$#!@#^) drugs should be the one(s) I use, and for what? ANTICOAGULANT THERAPY One of most common treatments in hospital & out 2 nd most
Timing the First Postoperative Dose of Anticoagulants Lessons Learned From Clinical Trials
[ Commentary ] Timing the First Postoperative Dose of Anticoagulants Lessons Learned From Clinical Trials Jeremy S. Paikin, MD ; Jack Hirsh, MD ; Noel C. Chan, MBBS ; Jeffrey S. Ginsberg, MD ; Jeffrey
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency London, 19 March 2009 EMEA/CHMP/BMWP/118264/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON NON-CLINICAL AND CLINICAL DEVELOPMENT OF SIMILAR BIOLOGICAL
Learning Objectives include:
Organization Frederick Memorial Hospital Solution Title Using Lean to Improve Quality Outcomes DVT Case Study Program/Project Description, including Goals: Hospital Acquired DVTs have become a very serious
DATA SHEET 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
DATA SHEET 1 CLEXANE AND CLEXANE FORTE * 2 QUALITATIVE AND QUANTITATIVE COMPOSITION CLEXANE Pre-filled syringes, ready-to-use: 20 mg injection enoxaparin sodium 20mg (equivalent to 2,000 IU anti-xa activity)
SR123781A: A New Once-Daily Synthetic Oligosaccharide Anticoagulant for Thromboprophylaxis After Total Hip Replacement Surgery
Journal of the American College of Cardiology Vol. 51, No. 15, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.03.007
Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement
The new england journal of medicine original article Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement Michael Rud Lassen, M.D., Gary E. Raskob, Ph.D., Alexander Gallus, M.D., Graham
Summary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Clexane Syringes 100mg/ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 20mg Injection 40mg Injection 60mg Injection
SUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Clexane Forte Syringes 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Pre-filled syringes: 120 mg Injection Enoxaparin sodium 120 mg (equivalent
SUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Clexane Multidose Vial 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Vials containing 300 mg enoxaparin (equivalent to 30,000 IU anti-xa
A BS TR AC T. n engl j med 363;26 nejm.org december 23,
The new england journal of medicine established in 1812 december 23, 2010 vol. 363 no. 26 Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement Michael Rud Lassen, M.D., Alexander Gallus,
Anticoagulation Treatment For Prevention Of Recurrent Thromboembolism In Patients With Cancer
Pacific University CommonKnowledge School of Physician Assistant Studies Theses, Dissertations and Capstone Projects 8-15-2009 Anticoagulation Treatment For Prevention Of Recurrent Thromboembolism In Patients
Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients
original article Apixaban versus for Thromboprophylaxis in Medically Ill Patients Samuel Z. Goldhaber, M.D., Alain Leizorovicz, M.D., Ajay K. Kakkar, M.D., Ph.D., Sylvia K. Haas, M.D., Ph.D., Geno Merli,
Abbreviations: DVT deep vein thrombosis; LMWH low-molecular-weight heparin; PE pulmonary embolism; VTE venous thromboembolism
Low Rate of Venous Thromboembolism After Craniotomy for Brain Tumor Using Multimodality Prophylaxis* Samuel Z. Goldhaber, MD, FCCP; Kelly Dunn, BA; Marie Gerhard-Herman, MD; John K. Park, MD, PhD; and
Newer oral anticoagulants for VTE and their relevance in India
Newer oral anticoagulants for VTE and their relevance in India 17/1/2014 M.Valliappan Senior Resident Department of Pulmonary Medicine Objectives Need for new drugs Individual drugs and their evidences
Use of Heparin and The Related Incidence of Heparin- Induced Thrombocytopenia in an Education and Research Hospital in Turkey
VOLUME 8 NUMBER 3 September 2017 JOURNAL OF CLINICAL AND EXPERIMENTAL INVESTIGATIONS ORIGINAL ARTICLE Use of Heparin and The Related Incidence of Heparin- Induced Thrombocytopenia in an Education and Research
Deep dive into anticoagulant reversal In 20 minutes so we won t dive too deep. Mark Crowther on behalf many Some slides modified from other sources
Deep dive into anticoagulant reversal In 20 minutes so we won t dive too deep Mark Crowther on behalf many Some slides modified from other sources 1 Disclosures Major disclosure: Paid consulting with Portola,
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
original article Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients Alexander T. Cohen, M.D., Theodore E. Spiro, M.D., Harry R. Büller, M.D., Lloyd Haskell, M.D., Dayi Hu, M.D., Russell
Lovenox weight calculator
P ford residence southampton, ny Lovenox weight calculator What Are the Treatments for Hemangioma on the Liver? Sciatic Nerve Surgery Recovery Time. How to Determine the Best Brand of Compression Stockings
Relative Effects of Two Different Enoxaparin Regimens as Comparators Against Newer Oral Anticoagulants. Meta-analysis and Adjusted Indirect Comparison
CHEST Original Research ANTITHROMBOTIC THERAPY Relative Effects of Two Different Enoxaparin Regimens as Comparators Against Newer Oral Anticoagulants Meta-analysis and Adjusted Indirect Comparison Chun
Use of modified intention to treat analysis in studies of direct oral anticoagulants and risk of selection bias.
Use of modified intention to treat analysis in studies of direct oral anticoagulants and risk of selection bias. Tristan Rainville, MD, a Madeleine Durand, MD, MSc, b Mikhael Laskine, MD, MSc, b a Centre
Drugs used in Thromboembolic Disease. Munir Gharaibeh, MD, PhD, MHPE Department of Pharmacology Faculty of Medicine October 2014
Drugs used in Thromboembolic Disease Munir Gharaibeh, MD, PhD, MHPE Department of Pharmacology Faculty of Medicine October 2014 Drugs used in Thromboembolic Disease Anticoagulants: Heparin. Oral anticoagulants.
Venous Thromboembolic Events (VTEs)
NURSING BEST PRACTICE GUIDE Venous Thromboembolic Events (VTEs) This document is one of the Myeloma Academy Nursing Best Practice Guides for the Management of Myeloma series. The purpose of this Guide
Guideline on core SmPC for human fibrinogen products
23 July 2015 EMA/CHMP/BPWP/691754/2013 Rev 1 Committee for Medicinal Products for Human Use (CHMP) Draft Agreed by Blood Products Working Party 27 November 2013 Adoption by CHMP for release for consultation
ORIGINAL CLINICAL INVESTIGATION
Rosencher et al. Thrombosis Journal 2012, 10:9 ORIGINAL CLINICAL INVESTIGATION Open Access Type of and the safety and efficacy of thromboprophylaxis with enoxaparin or dabigatran etexilate in major orthopaedic
UPDATE ON SPECIFIC ANTIDOTES FOR TARGET-SPECIFIC ORAL ANTICOAGULANTS
UPDATE ON SPECIFIC ANTIDOTES FOR TARGET-SPECIFIC ORAL ANTICOAGULANTS Junporn Kongwatcharapong (Pharm. D.) Clinical Pharmacist, Siriraj Hospital OUTLINE Introduction Approach to the management of TSOACs
UP AND COMING ANTICOAGULANTS AND HEMOSTASIS AGENTS
UP AND COMING ANTICOAGULANTS AND HEMOSTASIS AGENTS Jeffrey I Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke Foundation/
New Anticoagulants. Kenneth A. Bauer
New Anticoagulants Kenneth A. Bauer Traditional anticoagulant drugs, including unfractionated heparin and warfarin, have several limitations. New anticoagulants have been developed that target a single
Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Temporal Aspects.
Heparin Induced Eric Kraut, MD Professor of Internal Medicine The Ohio State University Medical Center Heparin Induced Heparin induced thrombocytopenia occurs in up to 5 % of patients receiving unfractionated
Analysis of Clinical Trials with Multiple Objectives
Analysis of Clinical Trials with Multiple Objectives Alex Dmitrienko (Mediana Inc) Regulatory Industry Statistics Workshop September 2017 Outline Regulatory guidelines FDA and EMA draft guidance documents
GUIDELINE REGARDING COLLECTION, VERIFICATION, AND SUBMISSION OF THE REPORTS OF ADVERSE EVENTS / REACTIONS OCCURRING IN CLINICAL DRUG TRIALS
1. PURPOSE This guideline is about the collection, verification, and submission of the reports of adverse events / reactions occurring in clinical drug trials, and code breaking methods. 2. DEFINITIONS
Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on. 30/11/2017 n/a. 22/11/2017 Annex II and PL
Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected
Denosumab for the prevention of skeletal related events in patients with multiple myeloma first line
NIHR Innovation Observatory Evidence Briefing: April 2017 Denosumab for the prevention of skeletal related events in patients with multiple myeloma first line NIHRIO (HSRIC) ID: 6619 NICE ID: 8815 LAY
Initial Dose 10,000 units Every 4 to 6 hours 5,000 to 10,000 units. Intermittent IV injection
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HEPARIN SODIUM IN 0.45% SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information
Analysis of the Anticoagulant Market
MEDICAL DEVICES PHARMACEUTICALS CHEMICALS FOOD & BEVERAGE ELECTRONICS Analysis of the Anticoagulant Market VPG Publications, Consulting, Clients www.vpgcorp.com VPG Market Research Reports www.vpgmarketresearch.com
newsletter november 06 Dr Peter Davidson, Pathologist in Charge Haematology
QML PATHOLOGY newsletter november 06 >> Low Molecular Weight Heparin (LMWH) Clinical Guidelines Dr Peter Davidson, Pathologist in Charge Haematology To aid the treating Doctor, we have devoted the November
If not heparin for bypass then what? Dr Tony Moriarty Consultant Cardiac Anaesthetist Birmingham United Kingdom
If not heparin for bypass then what? Dr Tony Moriarty Consultant Cardiac Anaesthetist Birmingham United Kingdom Heparin Discovered 1916, commercial available 1935 Heparin Is there an alternative, not really
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of antithrombin
Protocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Hemmelgarn BR, Moist LM, Lok CE, et al. Prevention of dialysis catheter
Cost-Effectiveness of Enoxaparin as Thromboprophylaxis in Acutely Ill Medical Patients in Spain
Volume 6 Number 2 2003 VALUE IN HEALTH Cost-Effectiveness of Enoxaparin as Thromboprophylaxis in Acutely Ill Medical Patients in Spain M.J.C. Nuijten, MD, MBA, 1 F. Antoñanzas Villar, PhD, 2 J. Kosa, MD,
January (San Francisco, CA) January 8, 2018
January 2017 J.P. Morgan 36 th Annual Management Healthcare Presentation Conference (San Francisco, CA) January 8, 2018 DISCLAIMER Certain information contained in this presentation relates to or is based
Monitoring oral anticoagulation Philosophy and controversies
Monitoring oral anticoagulation Philosophy and controversies Pall* T. Onundarson, M.D. National Hospital and University of Iceland School of Medicine Reykjavik Iceland *Paul, Paolo, Pablo. Non-adherence
INNOVANCE DTI Assay Delivering the Reliability Your Lab Needs to Confidently Test for Dabigatran
Eva-Maria Landmann Marketing Manager Hemostasis INNOVANCE DTI Assay Delivering the Reliability Your Lab Needs to Confidently Test for Dabigatran INNOVANCE DTI Assay* Introduction Clinical Information Dabigatran
Eileen Navarro MD, FACP Medical Officer, OCS, OTS, CDER, FDA
Eileen Navarro MD, FACP Medical Officer, OCS, OTS, CDER, FDA 1 www.fda.gov WHAT MEDICAL REVIEWERS CAN DO WITH STANDARDIZED DATA AND METADATA RECEIVED IN MODULE 5 Eileen Navarro, MD, FACP OCS/OTS/CDER/FDA
Acknowledgements. Expert Panel. Medication Safety Support Service (MSSS) Advisory Group. Why Anticoagulant Safety? Anticoagulation Principles
Ontario Medication Safety Support Service Anticoagulant Project Co-leads: Acknowledgements Carmine Stumpo, Toronto East General Hospital Kris Wichman, ISMP Canada Donna Walsh, ISMP Canada Funded by the
Venous thromboembolism (VTE) prevention in orthopedics: facts, controversies, and evolving management
Orthopedic Research and Reviews open access to scientific and medical research Open Access Full Text Article Review Venous thromboembolism (VTE) prevention in orthopedics: facts, controversies, and evolving
Office for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
STATEMENT SANDRA KWEDER, M.D DEPUTY DIRECTOR, OFFICE OF NEW DRUGS CENTER FOR DRUG EVALUATION AND RESEARCH U.S. FOOD AND DRUG ADMINISTRATION BEFORE THE
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville MD 20857 STATEMENT OF SANDRA KWEDER, M.D DEPUTY DIRECTOR, OFFICE OF NEW DRUGS CENTER FOR DRUG EVALUATION
1 st Quarter 2007 Earnings. April 19, 2007
1 st Quarter 2007 Earnings April 19, 2007 Forward-Looking Statement The statements in this presentation that are not historical facts are forward-looking statements based on current expectations of future
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Oral for Symptomatic Venous Thromboembolism The EINSTEIN Investigators* A BS TR AC T Background, an oral factor Xa inhibitor, may
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL SAFETY REPORTING DURING CLINICAL TRIALS IN SOUTH AFRICA This document has been prepared to serve as a guideline to those reporting adverse events occurring during the use of registered
Use of Low-Molecular-Weight Heparin in the Treatment of Venous Thromboembolic Disease: Answers to Frequently Asked Questions
Concise Review for Primary-Care Physicians Use of Low-Molecular-Weight Heparin in the Treatment of Venous Thromboembolic Disease: Answers to Frequently Asked Questions SCOTT C. LITIN, M.D., JOHN A. HEIT,
Anticoagulant therapy has historically consisted. A pharmacologic overview of current and emerging anticoagulants
A pharmacologic overview of current and emerging anticoagulants EDITH A. NUTESCU, PHARMD; NANCY L. SHAPIRO, PHARMD; AIMEE CHEVALIER, PHARMD; AND ALPESH N. AMIN, MD, MBA ABSTRACT For over 50 years, anticoagulant
Which is the best anticoagulant during primary PCI (p-pci) for STEMI?
ALPIC 2016 Friday, March 25 th, 2016 Round Table: Antithrombotic therapy for ACS-PCI Which is the best anticoagulant during primary PCI (p-pci) for STEMI? George Hahalis Associate Professor of Cardiology
Clinical Trials Development Resource for Hematologic Disorders (U24)
Clinical Trials Development Resource for Hematologic Disorders (U24) Diane Catellier, DrPH RTI International RTI International is a trade name of Research Triangle Institute. www.rti.org What is the U24
Final Appraisal Report:
Final Appraisal Report: Fondaparinux Sodium (Arixtra ) for the treatment of unstable angina or non-st segment elevation myocardial infarction (UA/NSTEMI) GlaxoSmithKline Advice No: 0608 Recommendation
Changes in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase
Clinical Hemorheology and Microcirculation 23 (2000) 213 218 213 IOS Press Changes in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase Lirong Jin
Verification of Disk Diffusion Tests
Verification of Disk Diffusion Tests Objectives 1. Describe disk diffusion tests 2. Describe process of FDA clearance of susceptibility tests 3. Discuss CLIA requirements for laboratory verification of
The importance of body size for bridging studies
The importance of body size for bridging studies Masato Kaneko, Takahiko Tanigawa, Ryosei Leo Kawai Clinical Sciences Japan, Bayer Yakuhin Ltd., Osaka, Japan ICH and guidelines related to bridging concept
JMP JMP Pro JMP Genomics JMP Clinical JMP Add-Ins
JMP FAMILY OF PRODUCTS: SOFTWARE FOR LIFE SCIENTISTS JMP JMP Pro JMP Genomics JMP Clinical JMP Add-Ins CLINICAL TRIAL DATA REVIEWS Randomized clinical trial remains the gold standard for evaluating efficacy
8. Clinical Trial Assessment Phase II
8. Clinical Trial Assessment Phase II Junko Sato, PhD Office of New Drug I, PMDA Disclaimer: The information within this presentation is based on the presenter s expertise and experience, and represents
Acquired Thrombotic Thrombocytopenic Purpura (attp)
Results of the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Hercules Study of in Patients with Acquired Thrombotic Thrombocytopenic Purpura Marie Scully, Spero Cataland, Flora Peyvandi, Paul Coppo,
Investor Presenta,on. Dawson Reimer President & COO. Albert D. Friesen, PhD. Chair & CEO
Investor Presenta,on Albert D. Friesen, PhD Chair & CEO Dawson Reimer President & COO March 31, 2015 Disclaimer This presentation is for informational purposes only and should not be considered as an offer
Understanding. (pomalidomide) capsules. Improving Lives Finding the Cure. Multiple Myeloma Cancer of the Bone Marrow
Multiple Myeloma Cancer of the Bone Marrow Understanding POMALYST (pomalidomide) capsules u-pom_en_2017_m3 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873)
Verification of Gradient Diffusion Strips
Verification of Gradient Diffusion Strips Objectives 1. Describe gradient diffusion tests 2. Describe process of FDA clearance of susceptibility tests 3. Discuss CLIA requirements for laboratory verification
Managing Risk and Uncertainty Through the Drug Life cycle. Recent FDA Initiatives. Theresa Mullin, PhD
Managing Risk and Uncertainty Through the Drug Life cycle Recent FDA Initiatives Theresa Mullin, PhD Director Office of Strategic Programs US FDA Center for Drug Evaluation and Research October 14, 2014
Media Release Medienmitteilung Communiqué Aux Médias
Sandoz launches Zarxio TM (filgrastim-sndz), the first biosimilar in the United States Launch follows March 6, 2015 FDA approval Sandoz One Source TM offers patient support services Holzkirchen, September
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
The new england journal of medicine original article Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis Harry R. Büller, M.D., Claudette Bethune, Ph.D., Sanjay Bhanot, M.D., Ph.D.,
BAXTER UNVEILS DESIGN ENHANCEMENTS TO FLOSEAL AND TISSEEL HEMOSTATIC AGENTS AT AORN MEETING
FOR IMMEDIATE RELEASE Media Contact Beth Mueller, (224) 948-5353 media@baxter.com Investor Contact Clare Trachtman, (224) 948-3085 BAXTER UNVEILS DESIGN ENHANCEMENTS TO FLOSEAL AND TISSEEL HEMOSTATIC AGENTS
IV tpa: 1996 to Present
IV tpa: 1996 to Present Where We ve Come From & What We ve Learned 1 Many of the things that seem impossible now will become realities of tomorrow. 2 Streptococcus Discovered back in the 1930s Activates
PRODUCT MONOGRAPH HEPARIN SODIUM INJECTION USP
PRODUCT MONOGRAPH HEPARIN SODIUM INJECTION USP For intravenous or subcutaneous use 1000 USP units per ml (preservative free) 1000 USP units per ml 5 000 USP units per ml 10 000 USP units per ml Anticoagulant
Alex C. Spyropoulos, MD; Judith S. Hurley, MS, RD; Gabrielle N. Ciesla, MS; and Gregory de Lissovoy, PhD, MPH
Management of Acute Proximal Deep Vein Thrombosis* Pharmacoeconomic Evaluation of Outpatient Treatment With Enoxaparin vs Inpatient Treatment With Unfractionated Heparin Alex C. Spyropoulos, MD; Judith
Apheresis Anticoagulant Removal. Oluwatoyosi Onwuemene, MD MS May 6th, 2017
Apheresis Anticoagulant Removal Oluwatoyosi Onwuemene, MD MS May 6th, 2017 Talk Outline Case presentation Factors associated with drug removal TPE s effects on hematologic parameters Anticoagulant properties
Update on New MS Therapeutics
Update on New MS Therapeutics William Meador, MD Assistant Professor AAN August 2017 Meeting Disclosures Clinical Trial Involvement: SPRINT-MS Trial MediciNova, ibudilast LemCog Sanofi/Genzyme, alemtuzumab
DR NEIL FISHER. Helicon Medical Writing Ltd, Director
PROFILE I am an experienced writer, skilled in writing and editing a wide range of medical communications and healthcare education documents for a variety of audiences. Integral to this is my command of
PREVELEAK Surgical sealant
PREVELEAK Surgical sealant Rx only Instructions for Use DEVICE DESCRIPTION PREVELEAK Surgical sealant (PREVELEAK) is a sealant developed to seal suture holes formed during surgical repair of the circulatory
Improving Outcomes of Cardiac Surgery with a Point-of-Care Based Transfusion Algorithm
Improving Outcomes of Cardiac Surgery with a Point-of-Care Based Transfusion Algorithm Summer Syed (local PI) Keyvan Karkouti Deputy Anesthesiologist-in-Chief, Toronto General Hospital, University Health
Passive vaccination as a global strategy for preventing RSV disease in infants. Filip Dubovsky MD MPH FAAP MedImmune March 2016
Passive vaccination as a global strategy for preventing RSV disease in infants Filip Dubovsky MD MPH FAAP MedImmune March 2016 Outline for Presentation Rationale for passive immunization for RSV prophylaxis